Ing. Galina Karabanovich, PhD.

Education, Academic and Scientific Degrees

2014 – PhD in Bioorganic chemistry (Faculty of Pharmacy, Charles University, Czech Republic),

2009 – Engineer (Faculty of Chemical and Biotechnology, Saint-Petersburg State Institute of Technology (Technical University), Russian Federation)

Working Experience

Since 2014 – Research fellow (FaF UK, Department of Organic and Bioorganic Chemistry)

Teaching

Since 2016 – teaching of Chemical Laboratory Techniques (practical classes) and General and Inorganic Chemistry (seminars) (Czech language, FaF UK)

Selected Posters at Conferences

• Gordon Research Conference: Tuberculosis Drug Discovery & Development, 2023, Barcelona, Spain

• EMBO Workshop on Tuberculosis, 2022, Institut Pasteur, Paris, France

• Gordon Research Conference: Tuberculosis Drug Discovery & Development, 2017, Lucca, Italy

Scientific grants

• 2023 – 2025: Member of the research team of Czech science foundation project 23-06558S - The role of signaling associated with DNA damage in development of anthracycline cardiotoxicity and its pharmacological impact

• 2021 – 2024: Member of the research team of the Czech Health Research Council project NU21-05-00446 "From hit-to-lead candidate - development of novel agents to combat tuberculosis"

• 2021 – 2023: Member of the research team of Czech science foundation project 21-16195S - Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta

• 2018 – 2020: Member of the research team of Czech science foundation project 18-08169S - Study of individual topoisomerase II isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines

• 2014 – 2017: Member of the research teams of the University project UNCE 204019/304019/2012 and Czech science foundation projects GA13-15008S and GA14-08423S, Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University

• 2010 – 2012: Principal Investigator of grant of the Grant Agency of Charles University 55610/2010 "Synthesis and properties of selenium analogues of sulfur antituberculosis drugs"

Research Interests

• Synthesis and structure-activity relationships of potential antitubercular agents

• Synthesis and structure-activity relationships of topoisomerase II inhibitors and dexrazoxane analogues

Publications and Citations (WOS)

• total number of publications (2009-2024): 20

• total number of citations including self-citations: 433; without self-citations: 380

• H-index: 13

Selected publications

• V. Keresteš, J. Kubeš, L. Applová, P. Kollárová, O. Lenčová-Popelová, I. Melnikova, G. Karabanovich, M. M Khazeem, H. Bavlovič-Piskáčková, P. Štěrbová-Kovaříková, C. A Austin, J. Roh, M. Štěrba, T. Šimůnek, A. Jirkovská. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Toxicological Sciences, 2024; kfae008, https://doi.org/10.1093/toxsci/kfae008 (IF2023 = 3.8)

• G. Karabanovich, V. Fabiánová, A. Vocat, J. Dušek, L. Valášková, J. Stolaříková, R. R. A. Kitson, P. Pávek, K. Vávrová, K. Djaout, K. Mikušová, A. R. Baulard, S. T. Cole, J. Korduláková, J. Roh. Both nitro groups are essential for high antitubercular activity of 3,5-dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles through the deazaflavin-dependent nitroreductase activation pathway. J. Med. Chem. 2024, 67, 81-109. (IF2022 = 7.3) 

• E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF2021 = 10.447)  

• P. Kollarova-Brazdova, A. Jirkovska, G. Karabanovich, Z. Pokorna, H. B. Piskackova, E. Jirkovsky, J. Kubes, O. Lencova-Popelova, Y. Mazurova, M. Adamcova, V. Skalicka, P. Sterbova-Kovarikova, J. Roh, T. Simunek, M. Sterba. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. J. Pharmacol Exp Ther., 2020, 373 (3), 402-415 (IF2020 = 4.03)

• A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF2021 = 8.039)

• G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019, 62, 8115-8139. (IF2019 = 6.205)

• G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016; 59 (6): 2362-2380 (IF2016 = 6.259).

Patents

• PCT patent application: WO2021/144746 A1 (PCT/IB2021/050285). Roh J., Štěrba M., Šimůnek T., Štěrbová P., Karabanovich G., Jirkovská A., Jirkovský E., Bavlovič Piskáčková H., Kubeš J., Jansová H., Kollárová P. Use of ICRF-193 derivatives and pharmaceutical preparations containing thereof for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs.

• Czech patent CZ 308557 B6. Roh J., Karabanovich G., Pavek P., Hrabálek A.: Substituovaný 1,2,4-oxadiazol, jeho použití a farmaceutický přípravek ho obsahující (Substituted 1,2,4-oxadiazole, its use and pharmaceutical preparation containing the same). bought by Svenox Pharmaceuticals LLC